Overview
Following subcutaneous or intramuscular administration, TB-500 achieves systemic distribution with preferential accumulation at sites of tissue damage, likely due to local actin concentration gradients and inflammatory chemokine signaling. Its short half-life (~4-6 hours estimated) necessitates twice-weekly dosing during loading phases. Angiogenic effects, detectable histologically in animal models within 3-5 days, contribute to improved oxygen and nutrient delivery. Stem cell recruitment via SDF-1/CXCR4 axis enhancement has been observed in preclinical cardiac models. Immunomodulatory effects include M2 macrophage polarization promotion, shifting the local microenvironment from pro-inflammatory to pro-regenerative.
Proposed mechanism
TB-500 works primarily by upregulating actin, a protein critical for cell migration, proliferation, and wound healing. It binds to actin monomers, promoting the formation of new blood vessels (angiogenesis), reducing inflammatory cytokines, and facilitating the recruitment of stem cells and progenitor cells to sites of injury. It also modulates integrin expression on cell surfaces, enhancing cell motility and tissue remodeling.
What the evidence supports
Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Graded Animal
Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair
· Nature (doi:10.1038/nature02910) · 2004
- [2]
Thymosin beta-4 induces adult epicardial progenitor mobilization and neovascularization
· Nature (doi:10.1038/nature05767) · 2007
- [3]
Thymosin beta4 and its role in tissue repair and regeneration
· Annals of the New York Academy of Sciences, 1269:32-37 · 2012
- [4]
The actin-sequestering protein thymosin-beta4 is a novel inhibitor of activation of antigen-specific T lymphocytes
· Journal of Immunology · 2000
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.